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Available online 14 July 2005Several nuclear hormone receptors have been associated with inflamma-
tory reactions. Particularly, liver X receptors (LXRs) have recently been
identified as key transcriptional regulators of genes involved in lipid
homeostasis and inflammation. LXRs are negative regulators of macro-
phage inflammatory gene expression. Multiple sclerosis (MS), a demyeli-
nating disease of the central nervous system of unknown cause, is
characterized by recurrent inflammation involving macrophages and
their inflammatory mediators. Sweden belongs to the countries with a
high MS incidence. In Italy, the MS incidence is lower, except on the
island of Sardinia where the incidence is even higher than in Sweden.
Subjects from Sardinia are ethnically more homogeneous, and differ from
Swedes also regarding genetic background and environment. We studied
mRNA expression of several nuclear hormone receptors in blood
mononuclear cells (MNC) from female patients with untreated relaps-
ing-remitting MS from Sassari, Sardinia, and Stockholm, Sweden. Sex-
and age-matched healthy controls (HC) were from both areas. mRNA
expression was evaluated by quantitative real-time PCR. We found
altered mRNA expression of LXRs, estrogen receptors (ERs), and
androgen receptor (AR) in MS. mRNA expression of both LXRA and
LXRB is lower inMS from Stockholm but not from Sassari. In particular,
LXRA mRNA expression was significantly lower in MS from Stockholm
as compared with all groups in the study includingMS from Sassari. Low
levels of ERA mRNA are seen in MS from both Stockholm and Sassari.
The splice variant ERBcx showed significantly higher mRNA expression
in MS from Sassari and Stockholm as compared with corresponding HC.
In particular, ERBcx mRNA in MS from Sassari was remarkably higher
as compared with all other groups in the study. Higher levels of AR
mRNA are present in HC from Sassari. The findings indicate that the
expression levels of anti-inflammatory nuclear receptor superfamily
genes in MS appear to reflect both ethnic and environmental influences.
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Multiple sclerosis (MS) is a chronic inflammatory disease of the
central nervous system of unknown aetiology. The clinical course
is usually characterized by relapses and remissions which, sooner
or later, are followed by disease progression and, finally, severe
disability. There is evidence for an altered immune balance in MS
patients both within the central nervous system and cerebrospinal
fluid (CSF) compartments and systemically. The extent of such
changes is still under study and their role remains enigmatic, as the
pathogenesis of MS is also elusive. Difficulties to identify the
cause and to clarify the pathogenesis can in part be attributed to the
complex disease traits that involve both genetic and environmental
factors. MS has profound heterogeneity in epidemiological
distribution, genetic susceptibility, clinical manifestations, patho-
logical lesion patterns, immunological alterations, and clinical
responses to the various therapies that are offered and that are at
best only partially effective. Taken together, such a complexity
seems to indicate a pathogenic heterogeneity in MS.
Prevalence studies point to a north–south gradient for MS in
Europe, with a clearly higher prevalence in e.g. Scandinavia
compared to countries in the south (Kurtzke, 1997). There is an
unexplained clustering of MS on the Italian island of Sardinia
when compared to the rest of Southern Europe, reaching
prevalence numbers that may even exceed those from e.g. Sweden.
The populations on Sardinia and in Sweden are environmentally as
well as ethnically distinct (Underhill et al., 2000; Sotgiu et al.,
2004). Sardinians are genetically more homogeneous and geo-
graphically more isolated compared to Swedes. Studies comparing
such diverse populations could provide pieces of information to
identify risk factors common to MS and, thereby, increase our
understanding of the disease pathogenesis.
In a recent study, we presented evidence for the existence in MS
in general of a pro-inflammatory state that is reflected by enhanced
expression of the cytokine IL-12p40 in both Sassari on Sardinia
and Stockholm, Sweden (Huang et al., 2005). A remarkable
heterogeneity was, however, observed between Sassari and Stock-
X. Liu et al. / Neurobiology of Disease 20 (2005) 961–968962holm for the expression of tumour necrosis factor-alpha (TNF-a),
IL-6, and indoleamine 2,3 dioxygenase (IDO). These findings
indicate heterogeneity traits of MS that may also have clinical
implications for e.g. future individualized MS therapy.
The present study aims at investigating mRNA expression of
nuclear hormone receptors (NHRs) which are associated with
inflammatory signalling. NHRs represent a large superfamily of
transcription factors with a plethora of biological functions
including development, metabolism, and homeostasis (Nagpal,
2003; Robinson-Rechavi et al., 2003). In particular, liver X
receptors (LXRs) and their relevant target genes have been shown
to play an important role not only in cholesterol and lipid
metabolism, but also in inflammatory processes and innate
immunity (Chawla et al., 2001; Joseph et al., 2004; Steffensen
and Gustafsson, 2004). LXRa null mice develop enlarged,
cholesterol-loaden livers and elevated serum cholesterol levels
upon exposure to high-cholesterol diets (Repa and Mangelsdorf,
2002). LXRa,h null mice accumulate cholesterol in liver, lung,
spleen, vessel walls, and CNS even on a normal diet with age
(Schuster et al., 2002; Wang et al., 2002). LXR ligand inhibits
atherosclerosis development in murine models of atherosclerosis
(Joseph et al., 2002). Recently, a role for LXRs has been described
in macrophage biology (Landis et al., 2002; Joseph et al., 2003),
including the protective functions of innate immunity and the
reduction of inflammation (Joseph et al., 2004).
The biological actions of LXRs relate in part to their ability to
regulate ATP-binding cassette transporter A1 (ABCA1) (Schmitz
and Drobnik, 2002) and the stearoyl CoA desaturase (SCD-1)
(Wang et al., 2004). Other NHR involved in inflammatory
reactions are three peroxisome proliferator-activated receptor
(PPAR) paralogues (PPARa, h/y, and g) (Chinetti et al., 2004),
the retinoic acid receptor paralogues (RARa, h, and g), and the
retinoid X receptor paralogues (RXRa, h, and g) (Costet et al.,
2003; Peng et al., 2004).
Among NHRs, estrogen receptors (ERs) (Offner, 2004) and the
steroid/NHR superfamily such as androgen receptor (AR) (Pal-
aszynski et al., 2004) have recently been reported to have anti-
inflammatory functions, and considered to have immunoprotective
effects in MS experimental animal models and, possibly, in MS
(Offner, 2004). ERa is also involved in LXR network and play a
roll in lipid metabolism.
In this study, inflammation-related NHRs, LXRs, and their
target genes, and the sex hormone receptors ERs, and the steroid/
NHR superfamily are examined at gene levels in highly matched
MS patients and healthy controls (HC) from two different parts of
the world with distinct populations and environments.Materials and methods
Patients
Fifteen MS patients from Sassari and 22 from Stockholm were
enrolled in the study. According to the study design, all MS
patients were females and fulfilled the Poser criteria for clinically
definite MS. The average age of the MS patients from Sassari and
Stockholm is 31 T 6 (20–40) and 32 T 7 (19–45) years,
respectively. All patients were diagnosed as having relapsing-
remitting MS, and all were in the phase of clinical remission for at
least 6 months at the time of sampling. All patients had MS-like
lesions on MRI of the brain and oligoclonal IgG bands in the CSFwhile undetectable in corresponding serum. The average levels of
the expanded disability status scale (EDSS) were 2 T 1 (0–4) and
2 T 1 (0–3.5), respectively. None of the patients had ever been
treated with the disease-modulating drugs interferon-h or Copax-
one, and none had received steroids for the last 6 months prior to
inclusion in the study. None of the patients included had ever
received any other immunosuppressive drugs. Fifteen age-matched
female HC from Sassari and 22 from Stockholm were enrolled
during the same time periods as the MS patients. The average age
of HC from Sassari and Stockholm was 30 T 5 (24–44) and 32 T 7
(21–44) years, respectively. The blood sampling period in Sassari
was between May 2002 and June 2003, and in Stockholm between
Feb. 2002 and June 2003.
Preparation and storage of mononuclear cells
All the materials and reagents used in the study were from the
same source and the same batch. 30 ml of blood from MS patients
and HC was obtained in heparinized tubes. Mononuclear cells
(MNC) were separated by density gradient centrifugation on
Lymphoprep (Nycomed, Oslo, Norway). Cell viability as measured
by Trypan blue exclusion always exceeded 95%. MNC were
divided into aliquots of 5–10  106 cells and pelleted by
centrifugation. The cells were then lysed in 1 ml of TRIZOL
reagent (Gibco, Paisley, UK), quickly frozen in liquid nitrogen, and
stored at 70-C until further use.
Isolation of total RNA, DNAse I treatment, and cDNA synthesis
Total RNA was isolated with RNeasyR Mini Kit (Qiagen,
Valencia, CA) according to the standard protocol. The concen-
tration and quality of the purified total RNA were determined
spectrophotometrically at OD260 nm, and the OD260/280 ratio was
calculated. To eliminate any residual genomic DNA, the RNA
samples were incubated with DNAse I (1 U/1 Ag of RNA;
Invitrogen, Carlsbad, CA) for 15 min at room temperature, and
inactivated by addition of 1 Al of 25 mM EDTA to the reaction and
heated at 65-C for 10 min. Synthesis of single-strand cDNA was
carried out using SuperScripti II RNase H Reverse Tran-
scriptase (Invitrogen), according to the manufacturer’s instructions.
The reaction was incubated at 25-C for 10 min, at 43-C for 60 min
and at 70-C for 15 min.
Real-time polymerase chain reaction and PCR analysis
Totally, 19 genes were selected for the study. PCR primers for
these selected genes and for h-actin used as internal control were
designed using Primer ExpressR Software version 2.0, a software
program specially provided with the 7700 SDS (Applied Bio-
systems, Foster City, CA). Primer sequences are shown in Table 1.
Real-time reverse transcriptase-polymerase chain reaction (RT-
PCR) assay on the basis of SYBR Green I (Ramos-Payan et al.,
2003) was performed using ABI PRISMER 7700 Sequence
Detection System (Perkin-Elmer–Applied Biosystems, Foster City,
CA). For each gene specific primer pairs, a dissociation curve
analysis was conducted to verify the specificity of the primer pairs.
Briefly, Master Mix (90 Al) containing 200 nM primers, 45 Al 2
qPCRi Mastermix Plus for Sybri Green I (Eurogentec, Ghent,
Belgium), and 2 Al cDNA (20 ng) were mixed before aliquoting in
triplicate to a 96-well microtiter plate. The cDNA was amplified
under the following universal conditions: one cycle at 50-C for 2
Table 1
The sequence of primers for real-time RT-PCR (all primers 5V–3V)
Primer Forward primer Reverse primer
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and 60-C for 1 min.
PCR data analysis
To correct for variations in input RNA amounts and efficiency
of reverse transcription, an endogenous Fhousekeeping_ gene, h-
actin, was also quantified and used to normalize the results. For
each sample, the normalized cycle threshold (Ct) value was
obtained by subtracting the Ct value of gene of interest from the
Ct value of beta-actin (normalized Ct = Ct of beta-actin-Ct of gene
of interest). The results are presented as relative fold changes with
h-actin as internal control.
Post-PCR data mining
All PCR assays showed intra- and inter-assay variations of less
than 5%. Statistical analysis was performed using the GraphPad
Prism version 4.0 (GraphPad Software, San Diego, CA). To
compare the significance between all MS patients and all HC,
unpaired t test or Mann–Whitney test (nonparametric distribution)
were used according to the distribution of data variances. A P
value < 0.05 was considered to indicate a significant difference
between groups. For multiple comparisons between subgroups,
parametric ANOVA test was used for normally distributed data,
followed by Bonferroni’s test if P < 0.05. Otherwise, Kruskal–
Wallis test was performed, followed by Dunn’s multiple compar-
ison test. All values are given as mean T SEM.Results
mRNA expression of LXRs and their target genes
LXR alpha (LXRa) and LXR beta (LXRh) are highly
homologous transcription factors belonging to the same sub-familyof NHR. LXRs function as master regulators of cholesterol
metabolism and control cholesterol efflux (Joseph et al., 2002)
and it was recently discovered that LXRs have protective function
in innate immunity (Joseph et al., 2004). In this study, we used
quantitative real-time polymerase chain reaction (PCR) to deter-
mine mRNA expression levels of both LXRa and LXRh in blood
MNC in female MS patients compared to age-matched female HC
from Sassari and Stockholm.
LXRa mRNA was significantly lower in all MS patients (n =
36) as compared with all the HC included (n = 36) (Fig. 1A; P <
0.05). Using multiple comparisons, lower levels of LXRa mRNA
were confined only to the MS patient group from Stockholm. MS
patients from Stockholm showed remarkably lower LXRa mRNA
(2.6 T 0.2, Fig. 1A) as compared with HC from Stockholm (3.4 T
0.2, P < 0.01), MS patients (3.8 T 0.2, P < 0.001), and HC (4.0 T
0.2, P < 0.001) from Sassari. No difference was detected between
the MS patients and HC from Sassari, and the HC from Stockholm.
mRNA expression of LXRh did not differ between the groups
comprising all MS patients (n = 37) and all HC (n = 37) (Fig. 1B).
However, the MS patients from Stockholm showed lower levels of
LXRh mRNA (2.9 T 0.3) as compared with HC from Stockholm
(4.1 T 0.4; P = 0.02) as was seen for LXRa. The MS patients and
HC from Sassari showed equal levels of LXRh mRNA (4.2 T 0.6
vs. 4.1 T 0.5, P > 0.05).
Several genes have been shown to be under direct or indirect
transcriptional control of LXRs either via their cognate response
elements in their respective promoters or via other factors
(Steffensen and Gustafsson, 2004). Of particular interest are the
ABCA1 and SCD. But in this study, we did not find significant
differences in expression patterns of ABCA1 or SCD-1 between
the whole group of MS patients and all the HC. Nor did we observe
any differences between MS patients and HC from Stockholm or
from Sassari (data not shown). Similar negative observations were
made for other NHRs including PPARa, h/y, and g; RARa, h, and
g; and RXRa, h, and g (data not shown).
Fig. 1. Liver X receptor (LXR) mRNA expression in blood mononuclear cells (MNC) from patients with multiple sclerosis (MS) and healthy controls (HC).
mRNA levels were quantified by real-time RT-PCR. mRNA values are normalized to h-actin. Values represent mean T SEM. Each sample is examined in
triplicate. (A) Lower levels of LXRa mRNA are detected in the group of all MS patients compared to all HC, and confined to MS patients from Stockholm as
compared to other groups in the study. (B) LXRh mRNA is lower in MS than in HC from Stockholm.
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The estrogen receptors ERa and ERh also belong to the NHR
superfamily and are estrogen inducible transcription factors.
Estrogen can inhibit the clinical signs and histopathological lesions
of experimental autoimmune encephalomyelitis (EAE) (Polanczyk
et al., 2003), and is used in clinical trials to treat MS (Offner,
2004). Using mutant mice in which ERa has been inactivated, it
was found that ERa was responsible for the estrogen-mediated
inhibition of EAE (Garidou et al., 2004). Most recently, ERs have
been shown to regulate the severity of EAE in female as well as
male mice (Polanczyk et al., 2004). Estrogen also inhibits lipid
uptake and reduces the development of atherosclerosis (Kramer
and Wray, 2002). ERhcx does not bind any ligand, nor does it
activate transcription. ERhcx preferentially heterodimerizes with
ERa, inhibiting ERa DNA binding and subsequent ERa signal-
ling. All 3 estrogen receptor variants were examined for mRNA
expression by quantitative real-time PCR in MS patients and HC
from both Stockholm and Sassari.
The whole group of MS patients showed a tendency of low
ERa mRNA expression (0.6 T 0.3, n = 37), but without a
statistically significant difference as compared with the whole
group of HC (0.06 T 0.3; n = 36; P = 0.5; Fig. 2A). Upon
subgrouping, the MS patients and HC based on their origin, HC
from Sassari showed higher ERa mRNA expression (0.6 T 0.5) as
compared with MS from the same area (0.6 T 0.3; P < 0.05), and
with MS (0.6 T 0.5; P < 0.05) and HC (0.5 T 0.3; P < 0.05)
from Stockholm. ERa mRNA expression was similar among MS
patients from Sassari and MS patients and HC from Stockholm
(Fig. 2A). No difference was observed in mRNA expression ofERh between the whole group of MS patients and all HC, nor
between the subgroups of MS patients and corresponding HC from
Sassari or from Stockholm (data not shown).
The whole group of MS patients showed significantly higher
ERhcx mRNA expression as compared to the whole group of HC
(3.9 T 1.0 vs. 1.8 T 0.3; P < 0.05) (Fig. 2B). Upon subgrouping,
MS patients from Sassari showed higher levels of ERhcx mRNA
expression as compared with corresponding HC (6.3 T 2.2 vs. 3.1 T
0.4, P < 0.05), and with MS patients (2.3 T 0.4) and HC (0.8 T 0.4)
from Stockholm (P < 0.05 for both comparisons). MS patients
from Stockholm showed significantly higher ERhcx mRNA
expression compared with corresponding HC (P < 0.05).
mRNA expression of other steroid/NHR superfamily members
The androgen receptor (AR), the glucocorticoid receptor (GR),
and the progesterone receptor (PR) are also members of the
steroid/NHR superfamily. They are involved in the lipid metab-
olism and the reduction of inflammation with the linkage to
LXRs. Therefore, these 3 receptors were also included in this
study.
In accordance with the results obtained for ERa mRNA
expression, the whole group of MS patients showed a tendency
of lower AR mRNA expression (1.3 T 0.3, n = 37) as compared
with all HC (1.9 T 0.3, n = 36), but without reaching statistical
significance (P = 0.2; Fig. 3). Multiple comparison analysis
showed that HC from Sassari had higher AR mRNA expression
(2.9 T 0.2) as compared with MS patients from the same area (1.4 T
0.3, P < 0.05), and MS patients (1.3 T 0.4, P < 0.05) and HC (1.1 T
0.3, P < 0.01) from Stockholm.
Fig. 3. Androgen receptor (AR) mRNA expression by MNC from MS and
HC. Levels of AR mRNA do not differ between all MS patients and all HC.
HC from Sassari have significantly higher AR mRNA levels as compared
with other groups in the study.
Fig. 2. Estrogen receptor (ER) mRNA expression by MNC from MS and HC. (A) Levels of ERa mRNA are lower in all the MS patients examined as
compared with all HC without statistical significance. HC from Sassari have higher levels of ERa mRNA when compared with the MS from Sassari and
subjects from Stockholm. Such a difference was not observed between MS and HC from Stockholm. (B) The splice variant ERhcx mRNA is significantly
higher in all MS as compared with all HC. MS from Sassari has remarkably higher ERhcx mRNA than HC from the same area, and from both MS and HC
from Stockholm. MS from Stockholm have higher ERhcx mRNA than HC from the same area ( P < 0.05).
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GR or PR between the whole group of MS patients and all HC, nor
between the subgroups of MS patients and their corresponding HC
from Sassari or Stockholm (data not shown).Discussion
In a recent study comparing MS patients and HC from Sassari
and Stockholm, we focused on pro- and anti-inflammatory
cytokines involved in aggressive autoimmune responses, and
reported the existence of a pro-inflammatory state in MS in
general (Huang et al., 2005). In the present work, we aimed at
identifying NHRs which are involved in innate immunity and
inflammation in the two populations under study.
We found that MS patients from Stockholm showed lower
mRNA expression of both LXR paralogues as compared with HC
from the same area. In particular, LXRa mRNA expression was
significantly lower as compared with all other groups including the
MS patient group from Sassari. In contrast, LXR levels were not
changed in MS from Sassari. LXRs have recently emerged as a
new target for the treatment of multiple diseases such as
inflammation, diabetes, and neurodegenerative diseases due to
their control of lipid metabolism and inflammatory response
(Whitney et al., 2003; Cao et al., 2004; Collins, 2004). However,
the involvement of LXRs in inflammatory diseases has up to now
not been verified. Recently, Tontonoz and colleagues used LXR
single- or double-knockout mice and documented that the animals
devoid of LXRs are more susceptible to Listeria monocytogenes,
developing higher bacterial burdens with higher demise following
infection (Joseph et al., 2004).
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exogenous lipids derived from the membranes of microbial
pathogens as well as by endogenous lipids generated from
cholesterol metabolism (Freeman and Moore, 2003). Lipid-
induced inflammatory responses can lead to a pro-inflammatory
state and to autoimmune responses which are thought to be
involved in a wide variety of human chronic inflammatory
diseases. Therefore, it has not come as a surprise that choles-
terol-reducing statins are claimed to have desirable immuno-
modulatory and anti-inflammatory effects in MS (Stuve et al.,
2003), although proof is still lacking for a linkage between lipid
metabolism and inflammation in MS. Being a link gene of
negative regulator of lipid metabolism and reduction of inflam-
mation, LXR expression would be expected to be lower in MS
than in HC. But this is not the case in MS from Sassari. The results
thus raise several questions. First, does the deficit of LXRs in MS
from Stockholm play an important role in the context of innate
immunity and/or anti-inflammation? Are cholesterol metabolism
and host defense related in MS from Stockholm but not in MS
from Sassari? If so, do LXRs mediate a link between lipid
metabolism and inflammation in MS from Stockholm? Does it
correlate to the different patterns of pro-inflammatory cytokine
expression as observed in MS from Stockholm vs. Sassari (Huang
et al., 2005)? Could LXR ligands be helpful to treat MS with low
LXR mRNA? Efforts to solve these questions might open up new
fields of MS research.
The role of sex hormones in MS can be verified by the well-
established clinical facts that two-thirds of MS patients are women,
the average age of onset overlaps the childbearing years, and the
frequency of relapses decreases in late pregnancy but increases in the
post-partum period (Paty and Ebers, 1998). This protective effect is
probably related to hormonal and immune response changes induced
by pregnancy. Estrogens may be responsible, at least in part, for this
protective effect (Devonshire et al., 2003). Estrogen is also known to
suppress certain infectious diseases (Salem, 2004), as well as T cell-
mediated EAE (Polanczyk et al., 2003; Garidou et al., 2004), an
animal model forMS. Estrogen exerts its effects through two nuclear
hormone receptors, ERa and h (Nilsson and Gustafsson, 2002). It
has recently been documented that ERa is the main estrogen
receptor in mouse adipose tissue, with ERa mRNA levels being
several hundred times higher than levels of ERh (Lundholm et al.,
2004). In addition, the effects of estrogen in EAE are dependent on
ERa but not ERh (Polanczyk et al., 2003). Mice with deleted ERa
develop systemic lupus erythematosus disseminatus (Shim et al.,
2004a), and mice with deleted aromatase develop Sjo¨gren’s
syndrome (Shim et al., 2004b). ERhcx, a nonligand binding splice
variant of ERh, shows preferential heterodimerization with ERa,
acting as antagonist of ERa.
MS from Sassari showed significantly lower mRNA expres-
sion of ERa but not ERh as compared with the HC from the
same area. Individuals from Stockholm, both MS and HC, also
showed lower levels of ERa mRNA as compared with HC from
Sassari. Levels of ERhcx were also lower in HC from Sassari as
well as in MS and HC from Stockholm, as compared with MS
from Sassari. Most interestingly, HC from Stockholm had
significantly lower ERh-cx mRNA levels as compared with MS
from the same area. These findings indicate a deficiency of ERa
mRNA in MS from both areas, but in a different pattern. ERs and
LXRs cross talk (at least in adipose tissue) (Lundholm et al.,
2004). This fact suggests that both NHRs, in concert, might play
a role in MS.AR expression plays an important role in the proliferation of
human prostate cancer and confers a better prognosis in breast
cancer (Yeap et al., 2004). A role for androgen is not well
documented in MS. But androgen is supposed to have protective
effects in male EAE mice (Bebo et al., 1998; Palaszynski et al.,
2004). The androgen receptor (AR) belongs to the classical
steroid hormone receptors and acts as a ligand-activated tran-
scription factor that binds DNA response elements as a
homodimer (McEwan, 2004). AR and its ligands regulate male
sexual development and body composition. AR is also involved
in the metabolism of lipids and maintenance of immunological
homeostasis. In addition, AR, GR, and PR are functionally
related to the ERs as well as to LXRs (Robinson-Rechavi et al.,
2003). Although all the individuals included in the present study
are females, there is a distinct difference in AR mRNA
expression in HC from Sassari, who showed remarkably high
levels of AR mRNA as compared to the corresponding MS from
Sassari, and to MS and HC from Stockholm. Considering its role
in lipid metabolism, inflammation and functional linkage with
ERs and LXRs, AR may serve as protective factor in MS from
Sassari.
Taken together, these results indicate that the nuclear
hormone receptors LXRs, ERs, and AR are altered in MS.
All these NHRs are associated with lipid metabolism and
inflammatory signalling, and have anti-inflammatory functions
(Nagpal, 2003). The present study was performed in highly
matched MS patients and HC from two different parts of the
world with distinct populations and environments. There is a
reduced mRNA expression of LXRs in MS from Stockholm but
not from Sassari. Low levels of ERa mRNA are seen in MS
from both Stockholm and Sassari but in a different pattern. High
levels of AR mRNA are present only in HC from Sassari which
may implicate AR as a protective factor. We conclude that anti-
inflammatory NHRs are involved in MS, and their gene
expression levels appear to reflect both ethnic and environ-
mental influences.Acknowledgments
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